Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

ting stent with clinically important benefits for patients," said Gregg W. Stone, M.D., Columbia University Medical Center; chairman, Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III U.S. pivotal clinical trial for XIENCE V.

Clinical Data Supporting XIENCE V

The robust clinical program for XIENCE V includes long-term data from a total of 1,362 patients enrolled in the SPIRIT FIRST, SPIRIT II and SPIRIT III trials, as well as continued access and post-approval programs that will enroll more than 14,000 XIENCE V patients.

The FDA approved XIENCE V based, in large part, on superior results from the 1,002 patient SPIRIT III U.S. pivotal clinical trial, in which XIENCE V demonstrated statistical superiority to TAXUS on the study's primary endpoint of in-segment late loss (vessel renarrowing) at eight months, with a statistically significant 50 percent reduction (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS). XIENCE V also demonstrated statistical non-inferiority to TAXUS in the co-primary endpoint of target vessel failure (TVF, cardiac events related to the stented vessel) at nine months, with an observed 20 percent reduction (7.2 percent for XIENCE V vs. 9.0 percent for TAXUS). TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).

In May 2008, Abbott presented two-year data from the SPIRIT III trial demonstrating that XIENCE V continues to deliver positive clinical benefits for patients. At two years, the XIENCE V demonstrated the following key results:

-- A 45 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (7.3 percent for XIENCE V vs. 12.8 percent for TAXUS, p-value=0.004)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (MI) or ischemia-driv
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Massachusetts og SHENZHEN ... Tech Solutions Co., LTD, (BGI Tech), et datterselskab ... lancering af en ny human whole exome-sekvenseringstjeneste baseret ... Complete Genomics, højt anset i branchen for at ... højfølsom registrering af alle typer varianter, blev købt ...
(Date:7/22/2014)... July 22, 2014 In chemical ... an increasingly common sight. The rapid rise of ... now well- established as a core gas measurement ... has made them the gas analyzer technology of ... conditions encountered in some processes have limited their ...
(Date:7/22/2014)... July 22, 2014 Holomic is ... the debut of its fluorescent immunoassay reader, the ... (AACC) meeting in Chicago, July 28-31, 2014. Available ... versions, the HRDR-300 is a highly sensitive, low-cost ... analyze fluorescent lateral flow immunoassays with high sensitivity ...
(Date:7/21/2014)... 21, 2014 Lawrence Livermore ... Board (WIB) and Las Positas College (LPC) recently ... education and hands-on training for veterans, officials recently ... at Las Positas is designed to help ... engineering technician careers, and establishes a pipeline of ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3
... Calif., May 28 CV Therapeutics,Inc. (Nasdaq: ... Nasdaq,marketplace rule 4350, the Company issued new inducement ... hiring, primarily in connection,with its commercialization efforts in ... cover an aggregate 151,800 shares of,common stock and ...
... with research institute to aid in successful mid-career changes, ... Center,( http://www.biocareercenter.com ) an online job board and careers ... Research,Institute who has developed Career Navigator -- a new ... within their fields with success --,to launch this new ...
... SoluLinK, Inc., a leader in,next-generation conjugation products ... of a new product, NanoLink(TM) Streptavidin Magnetic,Microspheres. ... of any commercially available polymer-encapsulated streptavidin,magnetic microsphere. ... throughput robotic applications where high biotin loads,must ...
Cached Biology Technology:CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2Online Career Service Turns Focus to 'Switching Gears' 2SoluLinK Introduces NanoLink(TM) Streptavidin Magnetic Microspheres 2
(Date:7/22/2014)... The challenges faced by researchers in modifying properties of ... a simple technique, thanks to recent innovative studies conducted ... , Through the use of a simple, efficient and ... NUS research teams, led by Professor Sow Chorng Haur ... of Science, demonstrated that the properties of two different ...
(Date:7/22/2014)... At some point, most kids will hear that drinking milk helps ... brain. But do these messages foster the idea that if something ... a new study in the Journal of Consumer Research , ... likely to eat it. , "We predicted that when food is ... to achieve a goal such as learning how to read or ...
(Date:7/22/2014)... have adapted to New York City,s human behaviour, allowing ... than their fellow squirrels in the woods. , Dr ... & Agriculture, led the study that proved eastern grey ... environments and prevent unnecessary responses when humans acted in ... , "As we rapidly increase the spread of ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3New York squirrels are nuts about city life 2
... (NASDAQ: ABPI) announces evidence that most, if not all ... fungal-induced inflammation as originally proposed by investigators at the ... of the Companys ongoing pivotal Phase 3 clinical trial ... of the antifungal amphotericin B 0.01% suspension. In ...
... most renowned physicists and engineers, OSA,s Frontiers in Optics meeting ... developments in the science of light. What: Frontiers ... 16-20, 2007 Where: Fairmont Hotel, San Jose, Calif. ... A new device that may help give sight to the ...
... great flood of Noahs generation really occur thousands of years ... ancient tsunami" Will pollution levels in our deep seas remain ... of the questions that are being addressed by a new ... non-profit research and education organization, EcoOcean. The team, ...
Cached Biology News:SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma 2Frontiers in Optics presents scientific advancements 2TAU scientists probe 'deep' questions aboard EcoOcean's environmental research ship 2TAU scientists probe 'deep' questions aboard EcoOcean's environmental research ship 3
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: filling ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... A simultaneous dual parameter assay ... poly caspase activity. Active caspases are ... peptide inhibitors, which are cell-permeable, non-cytotoxic ... caspases within the cells. At the ...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: